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Colistin is an antimicrobial peptide that has become the only remaining alternative for the
treatment of multidrug-resistant Gram-negative bacterial infections, but little is known of
how clinical levels of colistin resistance evolve. We use in vitro experimental evolution and
whole-genome sequencing of colistin-resistant Pseudomonas aeruginosa isolates from cystic
ﬁbrosis patients to reconstruct the molecular evolutionary pathways open for high-level
colistin resistance. We show that the evolution of resistance is a complex, multistep process
that requires mutation in at least ﬁve independent loci that synergistically create the
phenotype. Strong intergenic epistasis limits the number of possible evolutionary pathways to
resistance. Mutations in transcriptional regulators are essential for resistance evolution
and function as nodes that potentiate further evolution towards higher resistance by
functionalizing and increasing the effect of the other mutations. These results add to our
understanding of clinical antimicrobial peptide resistance and the prediction of resistance
evolution.
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T
he evolution of antibiotic-resistance has been intensely
studied since the ﬁrst resistant microorganisms were
discovered1. Theoretical work suggests that clinical use of
antibiotics with multiple cellular targets or complex resistance
mechanisms could reduce the rate of resistance evolution2,3.
Examples of clinically relevant antibiotics with multicomponent
resistance mechanisms are the glycopeptide vancomycin and the
cationic antimicrobial peptide colistin4–6.
Multicomponent antibiotic resistance is also a suitable model for
studying a central biological question: how do adaptations that
require acquisition of multiple mutations evolve? The mechanism
underlying the evolution of complex resistance mechanisms is not
completely elucidated7–11. Our work aims to shed further light on
the evolution of the complex resistance mechanisms that confers
high-level colistin resistance in Pseudomonas aeruginosa. Colistin
is active against many Gram-negative bacteria and is extensively
used to treat P. aeruginosa lung infections in cystic ﬁbrosis
patients12–15. The antimicrobial peptide is one of few remaining
effective drugs for treating multidrug-resistant Gram-negative
bacteria, in particular P. aeruginosa, Acinetobacter baumannii, and
Klebsiella pneumonia16. Several mechanisms that confer
low-level colistin resistance have been described, but our
understanding of the molecular pathways involved in high-level
resistance evolution is limited17–20. Among the non-mutational
P. aeruginosa mechanisms that increase tolerance to antimicrobial
peptides is remodelling of the outer membrane by addition of
4-amino-4-deoxy-L-arabinose (L-Ara4N) to the phosphate
groups of the lipopolysaccharide (LPS) lipid A region. The
enzymes responsible for this modiﬁcation are encoded by genes
in the arnBCADTEF-PA3559 (PA3552-PA3559) operon6,21–24.
Regulation of this operon is complex and involves several distinct
two-component regulatory systems that in concert promote arnB
transcription leading to increased LPS modiﬁcation in response to
low concentrations of divalent ions or the presence of cationic
peptides in the environment17,25–27. P. aeruginosa can also acquire
low to moderate level resistance through mutations in the
two-component regulators phoPQ and pmrAB depending
on strain background and experimental conditions24,28.
However, colistin-resistant clinical isolates from cystic ﬁbrosis
patients frequently have high-level resistance (minimum inhibitory
concentrations (MICs)4256mgml 1) indicating that additional
factors affect P. aeruginosa colistin resistance19,29,30.
We use whole-genome sequencing and experimental evolution
to identify the essential components of high-level colistin
resistance (colR) in P. aeruginosa. In addition, we reconstruct
evolutionary intermediates to determine the molecular
trajectories amenable to evolution of resistance and the inﬂuence
of epistatic interactions. We show that the evolution of high-level
colistin resistance is a complex, multistep process requiring
mutations in at least ﬁve independent loci that act synergistically
to create the phenotype and demonstrating that complex
resistance mechanisms can readily evolve de novo under the
right conditions such as drug gradients or stepwise selection.
Moreover, we show that mutations in transcriptional regulators
act as evolutionary nodes for further resistance evolution and that
the molecular pathways open for resistance evolution are shaped
by intergenic epistatic interactions. The identiﬁcation and
understanding of the genetic basis of colistin resistance and the
evolutionary process driving resistance evolution may facilitate
the development of tools to predict and manage resistance.
Results
pmrB mutations are insufﬁcient to explain high resistance. We
sequenced the genomes of B3-1811, B3-208, B3-20M and B3-CFI,
which are four P. aeruginosa isolates isolated from consecutive
sputum samples from a cystic ﬁbrosis patient with a long-term
chronic P. aeruginosa lung infection31. The patient had
undergone three months of oral ciproﬂoxacin and inhaled
colistin therapy31. The isolates B3-1811 and B3-208 were
colistin sensitive (colS) (MICr1 mgml 1); and B3-20M and
B3-CFI were colistin resistant (colR) (MIC4256 mgml 1). We
compared the genomes of the four isolates to identify mutations
that had accumulated since their most recent common ancestor,
that is mutations that most likely accumulated during the three
months that the patient underwent antibiotic therapy (Fig. 1).
All four isolates contained a 10-bp deletion within mutL, which
confers a hypermutator phenotype. We also identiﬁed 334
single nucleotide polymorphisms (SNPs; 98.8% transitions), and
72 small insertions or deletions (microindels) that differentiated
the isolates. The SNPs showed a perfect parsimonious pattern
of inheritance (that is the consistency according to a maximum-
parsimonious phylogenetic model is 1), reﬂecting a unidirectional
and clonal evolution of the B3 lineage since the most recent
common ancestor.
On the basis of the SNPs, we reconstructed the phylogenetic
relationship of the isolates (Fig. 1a), and found 198 SNPs and 39
microindels that distinguished the colR isolates from colS isolates
(Supplementary Data 1). Two of these mutations were located in
pmrB, which is involved in regulation of outer membrane LPS
modiﬁcation (Supplementary Table 1, Supplementary Data 1).
One of the pmrB mutations (742G4A leading to PmrBA248T)
was previously reported in other clinical colR P. aeruginosa
isolates and shown to be essential for resistance19,32. The pmrAB
genes appeared to be required for high-level resistance, since
deletion of pmrAB in the colR clinical isolate (B3-CFI) made it
more susceptible to colistin (Fig. 1b, Supplementary Table 2).
However, introduction of the pmrB allele from B3-CFI into
laboratory reference strain P. aeruginosa PAO1 by allelic
replacement produced only a two-fold increase in colistin MIC
(Fig. 1b, Supplementary Table 2). Moreover, allelic replacement
of pmrAB in B3-CFI with the PAO1 allele leads to a decrease in
resistance but not to the level of the sensitive B3 strains
(Supplementary Table 2). These results suggested that the pmrB
mutation contributed to the increased colistin resistance but did
not fully explain the high-level colR phenotype in the B3-20M and
B3-CFI isolates.
Experimental evolution of colistin resistance. The large number
of SNPs separating the colR and colS clinical isolates made
it impractical to experimentally establish additional factors
underlying high-level resistance in the isolates. We therefore
experimentally evolved colR in vitro by serial passaging of 16
parallel lineages of P. aeruginosa PAO1 with increasing
concentrations of colistin for 62 cycles. As controls, ﬁve
additional lineages were cultured without colistin. Of 16 lineages
cultured with colistin, nine developed stable high-level resistance
(MICs4256 mgml 1), while seven lineages did not evolve
resistance and went extinct during the experiment. All control
lineages remained susceptible to colistin (Fig. 2a).
One clone from each of the nine cultures that evolved stable
resistance and the ﬁve control cultures was selected for
whole-genome sequencing. We identiﬁed high-quality SNPs and
microindels by mapping sequence reads for each strain against
the PAO1 reference sequence. Polymorphisms found in all ﬁve
control strains were excluded from the analysis in order to avoid
false-positives caused by strain-speciﬁc (native) differences in the
parental PAO1 strain used in the experiments relative to the
published P. aeruginosa PAO1 sequence. All evolved colR strains
and one control strain had mutations in the DNA mismatch
repair gene mutS. Strains under colistin selection accumulated an
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average of 81 mutations and the control strain (CON1) with the
mutS mutation had 47 mutations. Only one to three mutations
were identiﬁed in the genomes of the remaining four control
strains (Supplementary Data 1).
To facilitate the identiﬁcation of mutations related to colR, we
assumed signiﬁcant parallel evolution between the nine surviving
experimental lineages. We focused on seven independent loci with
operons or genes that were nonsynonymously mutated in more
than three of the colR strains and with no mutations in control
strains (Fig. 2b). Nonsynonymous mutations were identiﬁed in
phoP, phoQ and pmrB genes, which are known regulators of
the LPS modiﬁcation operon, and in genes affecting lipid A
biosynthesis (lpxC (PA4406) or lpxD (PA3646)). In addition,
many strains had mutations in genes encoding components of
outer-membrane protein (OMP) assembly (opr86 (PA3648), seven
strains) or core LPS biosynthesis (PA5005, ﬁve strains; PA5008,
two strains; PA5194, eight strains). In addition, four colR
strains had mutations in ﬂeS/R (PA1098), which encodes proteins
in transcriptional regulation of ﬂagella (Fig. 2b, Supplementary
Table 1)33. The relative rates of nonsynonymous to synonymous
mutations (dN/dS) of genes mutated in one to two lineages
was 0.84 while the ratio in loci mutated in three to nine lineages
was 17.3 indicating a strong positive selection of mutations
(P(XZ52)Bpois(l¼ 3)o1 10 15, where l is the expected
number of nonsynonymous SNPs under neutral evolution)
(Supplementary Data 1).
Analysis of evolutionary pathways. To investigate the
evolutionary pathways involved in high-level colistin resistance,
we randomly chose a single colR strain (SNRC) from the
evolution experiment for further investigation. The ﬁve
resistance-associated mutations that this strain shared with at
least three other colR strains were transferred into the ancestral
PAO1 strain by allelic replacement (Fig. 3, Supplementary
Table 3). Alleles were introduced individually and in
combinations to produce a set of 32 (25) genotypes representing
all possible combinations of the mutant alleles (Fig. 3a). MIC
assays on the constructed genotypes showed that all ﬁve
mutations contributed to colR (Supplementary Table 3).
However, the evolutionary pathways to resistance were
constrained because mutations in lpxC, PA5005 or PA5194
increased resistance only when combined with other mutations
(Fig. 3a). Among the 120 (5!) possible paths to colR, only 22
resulted in an increase in drug resistance and were therefore
considered amenable to selection (Fig. 3a, Table 1). Only
mutations in the evolutionary nodes pmrB or opr86 increased
drug resistance in all backgrounds and mutations in these genes
provided the two possible ﬁrst steps to a two-fold increase in colR
as measured by MIC (Fig. 3a, Table 1). From the pmrB genotype,
colR progressed by acquisition of mutations in lpxC or opr86.
From the opr86 mutant, resistance progressed via mutations in
lpxC or pmrB, or a mutation in PA5005 followed by mutations in
lpxC or pmrB. Trajectories containing pmrB mutations were
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Figure 1 | High-level colistin resistance in clinical isolates is multi-factorial. (a) Maximum-parsimonious phylogenetic tree representing the evolutionary
relationship of P. aeruginosa isolates from patient B3. The tree shows the relationship between isolates based on 334 SNPs identiﬁed from genome
sequencing with an equal number of mutational events (that is, perfect consistency). The P. aeruginosa reference isolate PAO1 sequence was used as
outgroup to determine the root of the tree. Branch lengths are proportional to number of SNPs between isolates. Date of isolation is in parentheses after the
strain designation. (b) MICs (mgml 1) from microbroth dilution of P. aeruginosa PAO1 (PAO1), the B3 clinical isolates, B3-CFI pmrAB deletion (B3-CFI
D pmrAB) and P. aeruginosa PAO1 allelic replacement mutant with pmrB 634G4A, 742G4A allele from B3-CFI (PAO1 pmrBB3CFI). Horizontal lines represent
median MIC values of three or ﬁve replicates. Data underlying the ﬁgure is also presented in Supplementary Tables 2 and 3.
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considered more likely to be followed because of their greater
effects on colR (Table 1). To investigate if the result of the
SNRC reconstruction had a general applicability, we constructed
a quintuple phoQ779T4G lpxC161C4T PA50051502A4G
opr862305C4T PA5194717G4A (NJ268) mutant based on the
phoQ779T4G allele identiﬁed in strain SNRD and a quintuple
mutant based on the phoP245G4A allele of SNRB by introducing
it into strain NJ371 containing the opr862305C4T, lpxC161C4T,
PA5194717G4A, PA50051502A4G mutations from SNRC.
The resulting strains exhibited high colistin resistance with MICs
of 512 mgml 1 and 1024mgml 1, respectively, indicating that
the effect of the mutations on the resistance phenotype is not
restricted to the pmrB allele of SNRC strain (Supplementary
Table 3). Mutations were also found in pmrB, opr86 and lpxC in
the colR clinical strains B3-20M and B3-CFI. Introduction of
combinations of these mutations into P. aeruginosa PAO1
conferred resistance, although opr86 did not have an effect on
its own and lpxC increased drug resistance only in opr86
backgrounds (Fig. 3b and Supplementary Table 2). Moreover,
replacing the mutated alleles of pmrB and lpxC with
corresponding alleles from PAO1 in CFI signiﬁcantly reduced the
resistance but the resulting strains were still 32 and 128 times
more resistant compared to the sensitive clinical isolates
(Supplementary Table 2).
Epistatic interactions have an important inﬂuence on resistance
evolution9. We analysed epistasis among the mutations important
for colR by comparing changes in resistance when mutations were
added to backgrounds with different ﬁtness, measured as MIC
(Fig. 4). The combined effect of the ﬁve mutations (512) is 128
times greater than the expected effect of the individual mutations
(2 2 1 1 1¼ 4) indicating that there is a strong functional
relationship between them. The pmrB, opr86 and lpxC mutations
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Figure 2 | Experimental evolution of high-level colistin resistance in P. aeruginosa. (a) Colistin MIC values (mgml 1) for Wildtype (WT) ancestral P.
aeruginosa PAO1; SNRB through SNRP are colistin-resistant clones from surviving selection lineages. CON1 through CON5 are clones from control lineages
grown in LB medium in the absence of colistin. CON1 is a mutator strain with mutation in mutS. Colistin MIC was determined by microbroth dilution assays.
Horizontal lines indicate the median and symbols indicate biological replicates for MIC determination (at least three replicates were used per strain except
for CON5). (b) Parallel evolution of colistin resistance in vitro. Shown are operons or genes with mutations in more than three colistin-resistant strains. The
symbols contain the number of mutations at the locus. Strain SNRO did not have a mutation in ORF PA5194 but had a mutation immediately upstream and
a mutation downstream of the gene. Circles, genes affecting arnB-operon regulation; squares, genes affecting LPS biosynthesis or outer membrane
assembly; hexagons, genes affecting other functions; dotted line, in vitro selected strains and clinical isolates.
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had the largest effect on resistance in backgrounds with few
additional mutations. PA5194 and PA5005 affected
resistance only in backgrounds that already had increased
resistance (Fig. 4).
Mutated regulators potentiate high-level resistance evolution.
Introduction of mutations in pmrB, phoP, phoQ or opr86 into
P. aeruginosa PAO1 resulted in a two-fold increase in MIC,
whereas mutations in other genes identiﬁed in SNRC did not
confer detectable increases in drug resistance (Fig. 3a,b, and
Supplementary Table 3). We therefore hypothesized that
mutations in key regulators of the LPS modiﬁcation operon, such
as phoQ or pmrB might constitute critical ﬁrst steps in the
evolution of colR. To address this, we conducted an additional
serial transfer experiment with P. aeruginosa PAO1. In this
experiment, 11 of 15 selected lineages were eventually dominated
by clones with a 779T4G mutation causing a V260G shift in
PhoQ. In accordance with the hypothesis, we observed that clones
carrying this mutation dominated 8 of 11 populations by transfer
13, which corresponded to 6 serial passages at 0.5 mgml 1
colistin and two serial passages at 1mgml 1 colistin after 5 initial
transfers without colistin (Supplementary Fig. 1, Supplementary
Table 4).
To explore the signiﬁcance of initial mutations on the
evolution of colR, we used a microtiter resistance assay to
investigate the frequency of resistance to 16 mgml 1 and
32 mgml 1 colistin in the reconstructed genotypes. Mutations
in pmrB and phoQ potentiated the evolution of colR because
450% of wells containing strains with these mutant backgrounds
showed growth under selection, compared with 0–3% of
wells containing strains with wild type, PA5005 or PA5194
backgrounds (Fig. 5). An increased frequency of colR was also
observed in opr86 and lpxC mutant backgrounds. However, this
increased frequency was abolished in a DpmrAB DphoPQ
background indicating that the higher frequency was due to
mutations in pmrAB or phoPQ. When the higher colistin
concentration was used mutation frequency was reduced to
6–20% and 10–18% for the pmrB and phoQ mutant, respectively,
and 0–7% for the opr86 mutant (Fig. 5).
Table 1 | Effects on colistin resistance of mutations from
strain SNRC in the 16 possible allelic backgrounds.
Mutation Number of backgrounds on
which mean mutational effect
was
Mean proportional MIC
increase*
Positive Negative Negligiblew
pmrB 16 0 0 13.5
lpxC 12 0 4 6.2
opr86 16 0 0 5.7
PA5005 10 0 6 2.2
PA5194 6 0 10 1.3
*Geometric mean across all 16 alleles.
wZ2-fold changes in minimum inhibitory concentration (MIC) were considered signiﬁcant.
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Figure 3 | Evolutionary pathways to colistin resistance. (a) Phenotypes of the 32 (25) constructed genotypes in PAO1 based on mutations linked to
resistance in the colistin-resistant strain SNRC with colistin MIC (mgml 1) for each genotype. (b) Phenotypes of the 8 (23) constructed genotypes in PAO1
based on the alleles of pmrAB634G4A,742G4A (pmrABB3CFI), opr861525A4G (opr86B3CFI) and lpxC551A4G (lpxCB3CFI) linked to resistance in colistin-
resistant strains from patient B3 (B3-20M and B3-CFI) with colistin MIC (mgml 1) for each genotype. For both ﬁgures, node labels denote genes affected
by the mutation. Blue, low colistin MIC; red, high colistin MIC. Line thickness indicates relative MIC increase. Paths to high-level resistance deemed
inaccessible to selection because they had no increase in MIC at any step were omitted for clarity. Wildtype (WT), ancestral P. aeruginosa PAO1. Colistin
MIC was determined by microbroth dilution assays and values are the median of at least three biological replicates.
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These results were consistent with the low resistance of strains
lacking mutations in pmrB (Fig. 3a). In addition, resistance
to colistin required a functional arnB operon, supporting
the importance of mutations in pmrB, phoP or phoQ,
which all increased arnB operon expression (Fig. 5,
Supplementary Fig. 2).
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Figure 4 | Epistasis in colistin resistance evolution. Graphs show proportional MIC change in 16 allelic backgrounds with increasing MIC upon addition of
mutations in pmrB, opr86, lpxC, PA5194 or PA5005 from the colistin-resistant strain SNRC. Each point represents a single strain. In some cases, points are
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Figure 5 | Mutations in regulators potentiate evolution of high-level colistin resistance. Relative estimates for frequency of resistance to 16 mgml 1
colistin (unless otherwise indicated) was determined for different strains of P. aeruginosa PAO1 using 96-well microtiter plate assays. Plates were scored for
growth after 48 hrs by measuring optical density (OD) at 600 nm. Resistance as growth was scored for wells with OD40.06. Dotted horizontal line,
number of wells (96) investigated; wildtype (WT) P. aeruginosa PAO1; pmrB, phoQ, opr86, lpxC, PA5194 and PA5005, P. aeruginosa allelic replacement
mutants with mutations from SNRC or SNRD (phoQ779T4G). DpmrABDphoPQ, genes encoding the two-component systems were deleted; DarnB arnB gene
of the LPS modiﬁcation operon was deleted. Each point represents a single experiment. In some cases more than one symbol occupies the same space.
Horizontal lines show the median for each strain. Results are based on at least three biological replicates.
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Discussion
The molecular mechanisms underlying resistance and tolerance
towards antimicrobial peptides in Gram-negative bacteria are
very complex where multiple regulators inﬂuence susceptibility
primarily through a variety of lipopolysaccharide modiﬁcations17.
In this study, we investigated the evolution of colistin resistance
in P. aeruginosa, a major opportunistic and nosocomial pathogen.
Antibiotic resistance evolution can be severely constrained
by intramolecular pleiotropic effects8,9,11,34. In these studies,
most pathways to higher ﬁtness contained selectively neutral or
deleterious steps that made certain trajectories less likely to occur.
We showed that this also applies to stepwise evolution of complex
antibiotic resistance traits in which multiple genes interact to
establish the phenotype. All ﬁve mutations that were associated
with resistance in SNRC contributed to the resistance phenotype
but not in all combinations. Of the ﬁve single mutations, only
two (pmrB and opr86) measurably increased resistance alone
and these were the only mutations that increased MIC in all
backgrounds (Fig. 3a, Table 1). Pathways containing pmrB
mutations were more likely to lead to high resistance because
these mutations had greater effects than opr86 on colR,
presumably because of the strong direct effect of the pmrB
mutation on arnB expression (Supplementary Fig. 2).
Mutations in genes encoding regulators are important in the
adaptation process since mutations in regulatory elements can
affect a broad range of targets, increasing the probability of either
beneﬁcial or harmful effects compared to mutations in structural
genes35,36. The evolution of novel traits has recently been
addressed within the Escherichia coli long-term evolution
experiment and is proposed to be a three-step process in which
a potentiating background must evolve before a mutation can
emerge in the population that actualizes the novel phenotype37.
We were able to identify molecular details of evolutionary
pathways, and we could detect a clear pattern in the process of
evolution to high colR. At the start of the process, available
pathways were highly restricted: speciﬁc mutations were required
in genes encoding arnB operon regulators before additional
mutations could express their effects (Fig. 3) and be part of the
potentiating process described in the long-term evolution
experiment37. The PhoPQ and PmrAB two–component
systems have previously been implicated in the high colistin
resistance phenotype18–20. The parRS and cprRS two-component
regulatory systems are additional regulators involved in resistance
and tolerance regulation18,20,25,26. However, mutations in
parRS and cprRS were not found in our sequence data,
indicating that these pathways were not realized in our
experiment and in this particular CF patient. Recently, the cprA
gene has been implicated in affecting polymyxin B resistance20.
This gene is mutated in the colistin sensitive B3-1811 clinical
isolate but not in the highly colistin resistant isolates B3-20M
and B3-CFI31. It is possible that the genetic variation at the
cprA locus can explain some of the phenotypic differences
in absolute resistance values between the reconstructed
strains and the clinical isolates in addition to the variation
caused by the multiple mutations due to the mutator
phenotype.
In a recent study of the acquisition and reversion of colistin
resistance in P. aeruginosa lpxC was identiﬁed as a key component
of resistance evolution in vitro in addition to phoQ and pmrB38.
The study also shows that colistin resistance is dependent on
multiple mutations. However, in that study the mutations quickly
reverted to wild type when the strains were grown without
selection, a phenomenon not observed in our study38.
Clearly, multiple pathways could potentially lead to high
colistin resistance. However, only a limited number of these
pathways were realized in our study. Recently, Lind et. al. 36 have
investigated the basis of evolutionary parallelism by removing all
of the known pathways that could be mutated to produce the
‘wrinkly spreader’ phenotype in Pseudomonas ﬂuorescens and
experimentally selected for the phenotype36. They showed a large
diversity of hidden pathways that had not been discovered
earlier36 and propose a system of hierarchical rules where
mutations in negative regulators have a greater capacity to
translate mutation into phenotype due to the larger target size
available. If we apply these principles to explain the result of the
high colistin resistance evolutionary experiment, we ﬁnd that
regulatory mutations in pmrB and phoQ potentiated the effect of
the mutations in opr86, lpxC, PA5005 and PA5194. PhoQ acts as
a negative regulator of arnB expression and phoQ was the ﬁrst
gene to get a mutation in the replay experiment, which is
consistent with the hierarchal model (Supplementary Fig. 1,
Supplementary Table 4). However, in the experiment a speciﬁc
phoQ (PhoQV260G) mutation was preferentially selected, even
though any PhoQ-inactivating mutation leads to increased arnB
operon expression (Supplementary Fig. 2)28,39,40. This speciﬁc
phoQ mutation has also been identiﬁed in clinical and in vitro
evolved isolates with increased colR (refs 30,38,41). These ﬁndings
argue against inactivation of a negative regulator as an adequate
explanation for the selective preference of this speciﬁc mutation.
Moreover, the effects of the pmrB mutations are also more
complex to be straightforwardly explained as loss of function
mutations. The deacetylase lpxC and opr86 are essential genes and
affect lipid A biosynthesis and outer membrane (OM)
biogenesis42,43, which suggests that the mutations in these
genes are change of function mutations that affect peptide
target availability. In Lind et. al.36 such intragenic activating
mutations are one of the least likely category of adaptive
mutations making a straight forward translation of the results
of the ‘wrinkly spreader’ experiment to high colistin resistance
evolution difﬁcult36. Further studies are required to reveal the
exact function of LpxC and Opr86 mutations and their effect on
lipid A biosynthesis36. pmrB and opr86 are instrumental in the
resistance evolution process. Interestingly, these two genes are
among the genes most frequently associated with host adaptation
in P. aeruginosa CF isolates44,45. Recently, it has been shown that
pmrB mutation may be important in the adaptation process to
persistent lung colonization. A pmrB mutant had signiﬁcantly
increased ability to persist in a chronic respiratory infection
mouse model compared with not only the ancestral isolate but
also strains adapted to the mouse lung but lacking the mutation46.
The pmrB mutations were selected in the infection model without
any use of antimicrobial peptides. It is therefore possible the
chronic lung adaptation process selects for mutations that
increase the probability of colistin resistance evolution.
Several studies have addressed epistatic interactions on a
genomic level47–50. Key discoveries of these studies are that the
relative selective beneﬁt of a mutation is inﬂuenced by the ﬁtness
of the genetic background. The ﬁtness gain from many beneﬁcial
mutations is lower in relatively ﬁt backgrounds compared to less
ﬁt backgrounds and causing the rate of evolution to decrease over
time. The mutations identiﬁed here show strong synergistic
effects on colistin resistance since the MIC of the pmrB opr86
lpxC PA5194 PA5005 mutant was 512 mgml 1, a value 128 fold
greater than expected from the individual mutations
(2 2 1 1 1¼ 4) (Fig. 3a). The mutations in PA5194 and
PA5005 were beneﬁcial only in ﬁtter backgrounds (that is, with
higher colistin MIC). This observation could be due to that many
epistasis studies use growth rate as measure of ﬁtness48,49.
However, biochemical and biophysical constraints mean that
growth rate cannot increase indeﬁnitely, which could partly
explain the observed diminishing returns of beneﬁcial
mutations48. In our study, survival of the antibiotic challenge
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was a primary selective parameter, with growth as a secondary
factor once survival was achieved. Therefore, the effect of epistasis
on the evolutionary process and the pathways to ﬁtness will
depend on the selected trait and the nature of the selection
pressure. The evolution of high levels of colistin resistance in
P. aeruginosa enables the study of the process of adaptation in the
context of the clinically relevant area of antibiotic resistance. We
show that mutations in key regulators can act as evolutionary
nodes for rapid evolutionary change where multiple genetic loci
interact to produce a novel trait. Complex resistance mechanisms
can therefore readily evolve, only requiring an ordered sequence
of mutations where potentiating mutations, which could be
selected by unrelated factors such as host adaptation, open up
for further resistance evolution. Mutations with little or no
individual ﬁtness beneﬁt form strong synergistic interactions
when functioning together. More in depth knowledge about the
evolution of complex antibiotic resistance mechanisms may
facilitate new ways to predict antibiotic resistance evolution and
novel tools for resistance management.
Methods
Strains and growth conditions. The bacterial strains used in this study are listed
in Supplementary Table 5. Escherichia coli and P. aeruginosa strains were routinely
grown in Luria-Bertani (LB) broth. For plasmid maintenance in E. coli, medium
was supplemented with 8 mgml 1 tetracycline (Tc), 6 mgml 1 chloramphenicol or
100mgml 1 ampicillin (Ap). For marker selection in P. aeruginosa, 30mgml 1
gentamycin (Gm), 40mgml 1 tetracycline (Tc), or 200mgml 1 carbenicillin (Cb)
were used as appropriate.
Serial transfer experiments. Sixteen parallel lineages of P. aeruginosa PAO1 were
serially propagated in LB medium with increasing concentrations of colistin for 62
transfers. Five additional lineages were cultured in the absence of colistin as
controls. Cultures were grown in shaking incubators at 37 C and transferred twice
daily by inoculating into 5ml fresh medium with 50 ml culture for a daily dilution
of 1:10,000. All cultures were initially grown in the absence of colistin for ﬁve
transfers after which, the positive selection lineages were subjected to a sub-MIC
concentration of colistin (0.5 mgml 1). Colistin concentrations were doubled when
vigorous growth was observed. By the end of the experiment, 9 of 16 lineages
cultured in the presence of colistin had developed stable high-level resistance
(MIC4256 mgml 1). Seven lineages were extinct and all control lineages
remained susceptible to colistin. One clone from each lineage was isolated and
stored in 25% glycerol at  80 C. Stability of the resistance phenotype was tested
by serial passage in LB broth without antibiotic for ﬁve passages. All strains
remained highly colistin resistant.
MIC determinations. MIC was determined by microbroth dilution assay in
96-well microtiter plates with LB broth containing two-fold serial dilutions of
antimicrobial substance incubated for 24 h according to Wiegand et al.51. The MIC
values reported in this study are the median of at least three biological replicates
(except for CON5) and we generally saw very good reproducibility, for example 20
out of the 32 reconstructed strains for the 5 selected mutations in SNRC showed no
variation among replicates.
Mutation frequency estimation. A relative estimate for the frequency of
resistance to 16 mgml 1 and 32 mgml 1 colistin was determined for P. aeruginosa
PAO1 strains by a 96-well microtiter plate assay. Tubes with 10ml LB medium
were inoculated from a single colony and incubated with shaking overnight at
37 C. The next day, 1.0 107 colony forming units were added to wells of 96-well
microtiter plates with LB medium containing 16 mgml 1 or 32mgml 1 colistin
and incubated at 37 C with shaking for 48 h. Plates were scored for growth by
measuring optical density at 600 nm (OD600). Growth was deﬁned as
OD60040.06.
In vitro DNA manipulation. Plasmid DNA was puriﬁed using NucleoSpin Plasmid
EasyPure kit (Macherey-Nagel, Du¨ren, Germany) according to the manufacturer’s
instructions. Restriction enzymes were purchased from (Thermo Fisher Scientiﬁc,
Waltham, USA). PCR was performed in a T3 Thermocycler PCR machine from
Biometra using Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientiﬁc,
Waltham, USA), primers in Supplementary Table 6 and puriﬁed genomic DNA as
template. Plasmid DNA was treated with modifying enzymes and restriction
endonucleases, ligation of DNA fragments with T4 ligase, and electroporation of
bacterial strains were performed using standard methods52. In short, PCR products
were prepared for blunt-end ligations using Fast DNA End Repair kit (Thermo
Fisher Scientiﬁc, Waltham, USA), ensuring 50-phosphorylated, blunt-ended DNA
products or was prepared for sticky-end ligation, with primer design ensuring
restriction sites for SacI and XbaI. PCR products and digested plasmids were
puriﬁed NucleoSpin Extract II kit (Macherey-Nagel, Du¨ren,Germany) according to
the manufacturer’s instructions. Ligations were performed using the Rapid DNA
Ligation Kit (Thermo Fisher Scientiﬁc, Waltham, USA) according to
manufacturer’s instructions. For blunt-end ligations the pNJ1 plasmid was digested
with PstI restriction enzyme and blunt-ended and dephosphorylated, to prevent
re-ligations. For sticky-end ligations pNJ1 was digested using SacI and XbaI
restriction enzymes. DNA was ligated using Rapid DNA Ligation Kit (Thermo
Fisher Scientiﬁc, Waltham, USA) according manufacturer’s instructions. The
resulting plasmids were transformed into electrocompetent E. coli CC118lpir
using a Gene Pulser (Bio-Rad, Hercules,CA, USA) as recommended by the
manufacturer with 100ml bacterial cells and 10–100 ng DNA.
Generation of deletion mutants. Gene disruption cassettes were prepared by PCR
as described by Choi and Schweizer53 and transformed into plasmid pNJ1
(Supplementary Table 7). Brieﬂy, a set of overlapping PCR reactions were set up
using the primers presented in Supplementary Table 6 to produce DNA fragments
with a gentamycin resistance marker (GMR) ﬂanked by gene speciﬁc sequences.
These fragments were subsequently blunt-end cloned into the plasmid pNJ1.
Gene disruption cassette containing plasmids were transferred into P. aeruginosa
PAO1 or mutants by triparental mating using the helper strain E. coli HB101/
pRK600. Allelic exchange as indicated by a sucrose-resistant, Gm-resistant, Tc-
sensitive phenotype (or Cb-sensitive when pEX18ApGW plasmids were used) was
veriﬁed by PCR using gene-speciﬁc primers. Generation of unmarked deletion
mutants was achieved by transforming electro competent P. aeruginosa with pFLP2
as described previously53. Brieﬂy, 6ml of an overnight culture of P. aeruginosa
PAO1 and mutants, grown in LB medium was harvested in four microcentrifuge
tubes by centrifugation (1min, 1,3000g) at room temperature. Each pellet was
re-suspended in 1ml fresh 300mM sucrose and centrifuged. This was repeated two
times and the pellets were then combined in a total of 100 ml 300mM sucrose.
1 microliter of pFLP2 was added to a 2mm gap width electroporation cuvette and
mixed with 100 ml of electrocompetent cells. The electroporation was performed
using the settings: 25 mF, 200O and 2.5 kV. After applying a pulse, 1ml of pre-
warmed LB medium was added immediately, and the cells were transferred to glass
test tubes and incubated for 1–1.5 h at 37 C. After phenotypic expression, the cell
suspension was diluted 1:1,000 and 1:10,000 in LB, and 50 ml aliquots were plated
on LBþCb200 plates and incubated over night at 37 C. Transformants were
puriﬁed for single colonies on LBþCb200 plates. Sixteen single colonies were
tested for antibiotic-susceptibility on LBþGm30 plates and on a LBþCb200 plate.
Two Gms Cbr isolates were streaked for single colonies onto a LBþ 5% sucrose
plate and incubated at 37 C until sucrose-resistant colonies appeared. Sixteen
sucrose-resistant colonies were retested on LBþ 5% sucrose plates and LBþCb200
plates Then two sucrose-resistant and Cbs colonies were streaked on LB plates
without antibiotics and patched onto LBþGm30 and LBþCb200 plates to
conﬁrm their Gms Cbs phenotype. Excision of the Gmr marker and the absence of
recombination between remaining FRT sites were veriﬁed by colony PCR.
Genetic reconstruction of intermediates. Mutations from colR strains were
transferred via allelic replacement constructs (Supplementary Table 7) into
P. aeruginosa PAO1 and mutants by triparental mating using the helper strain
E. coli HB101/pRK600. Merodiploids were selected by plating the conjugation
mixture on LB agar plates with 40 mgml 1 Tc and followed by incubation until
colonies appeared. Colonies were restreaked on selective plates and single colonies
were streaked on 5% (w/v) sucrose LB agar plates (without NaCl). Sucrose-resistant
and Tc-sensitive colonies were restreaked on sucrose LB agar plates and screened
for the mutated allele by PCR with mutation-speciﬁc primers or by PCR
followed by restriction fragment length polymorphism (PCR/RFLP) analysis with
appropriate restriction enzymes. All mutants were veriﬁed by Sanger sequencing at
LGC Genomics (Germany). All strains were constructed in the order indicated in
Fig. 3 with the exception of the BDE combination (NJ463), which was constructed
in the following order: D (NJ81) -4 DE (NJ363) -4 BDE (NJ463) and the BCDEA
(AFP86) strain was constructed by introducing the pmrBSNRC allele
(pmrB524C4T(P175L)) into BCDE (NJ371).
Gene expression analysis. Expression of the arnB operon was investigated using
an arnB promoter fusion to green ﬂuorescent protein (GFP)39. Three independent,
exponentially growing cultures were generated and GFP ﬂuorescence of cells
was quantiﬁed using a FACSCalibur ﬂow cytometer (Becton Dickinson) and
normalized to the GFP ﬂuorescence of the SM2467 strain, which constitutively
express GFP.
Genome sequencing and mutation analysis. Genomic DNA was prepared from
P. aeruginosa isolates using a Wizard Genomic DNA Puriﬁcation Kit from
Promega and fragmented by acoustic shearing on a Covaris E210 with the standard
protocol for 300 bp fragments (duty cycle 10%, intensity 4, cycles per burst 200,
time 80 s). Fragmented DNA was puriﬁed using Qiaquick PCR puriﬁcation kit
from Qiagen, and end-repaired with End-It DNA End-Repair kit from Epicentre.
End-repaired DNA was puriﬁed with Agencourt AMPure XP beads (1:1 ratio), and
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dA was added to the 30 of blunt DNA fragments using Klenow. DNA was puriﬁed
using AMPure XP beads (ratio 1:1), and barcoded adaptors with a dT-overhang
was ligated to DNA fragments using Fast-Link DNA Ligation kit from Epicentre.
DNA was puriﬁed using AMPure XP beads (ratio 0.9:1) to remove un-ligated
adaptors, and DNA libraries was ampliﬁed using standard to Illumina primers to
facilitate sequencing on an Illumina GAIIx machine generating 75-bp single reads
to obtain a minimum of 2,363,822 reads from each of the genomic libraries.
Mutations were identiﬁed by aligning reads to the P. aeruginosa PAO1
reference genome (Genbank accession no. NC_002516.2) with Novoalign
(Novocraft Technologies)54, used GATK for realignment around indels55, and
produced pileups of the read alignments by SAMtools release 0.1.7 (ref. 56).
SNPs were extracted from the read pileup by the following criteria: (1) quality
scores (Phred-scaled probability of sample reads being homozygous reference) of at
least 50 (i.e., Pr10 5), (2) root-mean-square (RMS) mapping qualities of at least
25, (3) minimum of three reads covering the position and (4) only unambiguous
SNP calls. Microindels were extracted from the read pileup by the following
criteria: (1) quality scores of at least 500, (2) RMS mapping qualities of at least 25
and (3) support from at least one-ﬁfth of the covering reads as previously described
in Marvig et. al.44.
To avoid false-positives caused by strain-speciﬁc (native) differences relative to
the published genome sequence of P. aeruginosa PAO1, we excluded
polymorphisms speciﬁc to the genetic background. This meant that
polymorphisms found in all ﬁve control strains (cycled without colistin) were
excluded from analysis of the PAO1-derived isolates, and that polymorphisms
shared by all four B3 isolates were excluded from analysis of B3 isolates.
Data availability. Sequence reads from all isolates are deposited in the Short Read
Archive under accession numbers ERP002380 (B3 isolates) and ERP002381
(PAO1 derived isolates). The authors declare that the data supporting the ﬁndings
of this study are available within the article and its supplementary information ﬁles.
Bacterial strains and vectors are available from the corresponding author upon
request.
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